1-20 of 69
Philip A. Thompson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Clinical Trials & Observations
Philip A. Thompson, Jaya Srivastava, Christine Peterson, Paolo Strati, Jeffrey L. Jorgensen, Tyler Hether, Michael J. Keating, Susan M. O’Brien, Alessandra Ferrajoli, Jan A. Burger, Zeev Estrov, Nitin Jain, William G. Wierda
Blood (2019) 134 (22): 1951–1959.
DOI: https://doi.org/10.1182/blood.2019001077
Published: 2019
Includes: Supplemental data
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, MD, Michael J Keating, MBBS, Philip A. Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Marina Y Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MDMSc, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Blood (2019) 134 (Supplement_1): 34.
DOI: https://doi.org/10.1182/blood-2019-131847
Published: 2019
Journal Articles

Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells

Uri Rozovski, MD, David M. Harris, PhD, Ping Li, PhD, Zhiming Liu, BS, Taghi Manshouri, PhD, Ivo Veletic, MD, Preetesh Jain, MBBS,MDDM,PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, Srdan Verstovsek, MD PhD, William G. Wierda, MD PhD, Michael J Keating, MBBS, Zeev E. Estrov, MD
Blood (2019) 134 (Supplement_1): 3018.
DOI: https://doi.org/10.1182/blood-2019-124014
Published: 2019
Journal Articles

Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL

Uri Rozovski, MD, David M. Harris, PhD, Ping Li, PhD, Zhiming Liu, BS, Taghi Manshouri, PhD, Ivo Veletic, MD, Preetesh Jain, MBBS,MDDM,PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, Srdan Verstovsek, MD PhD, William G. Wierda, MD PhD, Michael J Keating, MBBS, Zeev E. Estrov, MD
Blood (2019) 134 (Supplement_1): 3024.
DOI: https://doi.org/10.1182/blood-2019-124183
Published: 2019
Journal Articles

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ekaterina Kim, MS, Hongying Zhang, MD PhD, Mariela Sivina, Alicia Vaca, PhD, Philip A. Thompson, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD, Jan A. Burger, MD PhD
Blood (2019) 134 (Supplement_1): 3051.
DOI: https://doi.org/10.1182/blood-2019-124473
Published: 2019
Journal Articles

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Courtney D. DiNardo, MDMSc, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro N. Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD
Blood (2019) 134 (Supplement_1): 2637.
DOI: https://doi.org/10.1182/blood-2019-127803
Published: 2019
Journal Articles

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc
Blood (2019) 134 (Supplement_1): 738.
DOI: https://doi.org/10.1182/blood-2019-128909
Published: 2019
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Koji Sasaki, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD
Blood (2019) 134 (Supplement_1): 357.
DOI: https://doi.org/10.1182/blood-2019-131939
Published: 2019
Journal Articles

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Philip A. Thompson, MBBS, Michael J Keating, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Prithviraj Bose, MD, William G. Wierda, MD PhD
Blood (2019) 134 (Supplement_1): 358.
DOI: https://doi.org/10.1182/blood-2019-129230
Published: 2019
Journal Articles

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Prithviraj Bose, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Marina Y Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSc, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Blood (2019) 134 (Supplement_1): 359.
DOI: https://doi.org/10.1182/blood-2019-131732
Published: 2019
Journal Articles

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc
Blood (2019) 134 (Supplement_1): 645.
DOI: https://doi.org/10.1182/blood-2019-128547
Published: 2019
Journal Articles

MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers

Vivian M. Liu, MD, Romain Guièze, MD, Daniel Rosebrock, Alexis A Jourdain, PhD, María Hernández-Sánchez, PhD, Aina Zurita Martinez, Elisa Ten Hacken, PhD, Philip A. Thompson, MBBS, Julian Bryan Iorgulescu, MD PhD, Shuqiang Li, PhD, Matthew S. Davids, MD, Jennifer R. Brown, MD PhD, Ana Lako, Zoe B. Ciantra, Matthew A. Lawlor, William G. Wierda, MD PhD, Anthony G. Letai, MD PhD, Donna S Neuberg, ScD, Christopher J. Ott, PhD, Ignaty Leshchiner, PhD, Vamsi Mootha, MD, Gad Getz, PhD, Catherine J. Wu, MD
Blood (2019) 134 (Supplement_1): 1284.
DOI: https://doi.org/10.1182/blood-2019-131336
Published: 2019
Journal Articles

Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Bachar Samra, MD, Nicholas J. Short, MD, Joseph D. Khoury, MD, Rashmi Kanagal-Shamanna, MD, Marina Y Konopleva, MD PhD, Nitin Jain, MD, Courtney D. DiNardo, MDMSc, Rita Khouri, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Nicole Tippett, RN, Rebecca Garris, MSc, Victoria Jeanis, RN, Naval G. Daver, MD, Philip A. Thompson, MBBS, Musa Yilmaz, MD, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Farhad Ravandi, MD, Elias Jabbour, MD
Blood (2019) 134 (Supplement_1): 1296.
DOI: https://doi.org/10.1182/blood-2019-128619
Published: 2019
Journal Articles

Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen

Caitlin R. Rausch, PharmD, Shilpa Paul, PharmD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Nicholas J Short, MD, Koji Sasaki, MD, Maria Khouri, Jovitta Jacob, RN, Kathryn S Montalbano, RN, Philip A. Thompson, MBBS, Nitin Jain, MD, Musa Yilmaz, MD, Kiran Naqvi, MDMPH, Maro N. Ohanian, DO, Patrice Nasnas, MD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD
Blood (2018) 132 (Supplement 1): 1417.
DOI: https://doi.org/10.1182/blood-2018-99-113645
Published: 2018
Journal Articles

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Nicholas J Short, MD, Farhad Ravandi, MD, Maria Khouri, Guillermo Garcia-Manero, MD, Naval G. Daver, MD, Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Nitin Jain, MD, Ghayas C. Issa, MD, Jovitta Jacob, RN, Rebecca E. Garris, MSc, Musa Yilmaz, MD, Philip A. Thompson, MBBS, Patrice Nasnas, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD
Blood (2018) 132 (Supplement 1): 34.
DOI: https://doi.org/10.1182/blood-2018-99-115271
Published: 2018
Journal Articles

Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies

Romain Guieze, MD, Vivian M Liu, Daniel Rosebrock, Alexis Jourdain, PhD, María Hernández-Sánchez, PhD, Aina zurita Martinez, Sun Jing, PhD, Kaitlyn J Baranowski, Philip A. Thompson, MBBS, Heo Jin-Mi, PhD, Zacchary Cartun, Ozan Aygun, PhD, Giulia Notarangelo, Dimitri Livitz, BS, Shuqiang Li, PhD, Matthew S. Davids, MD, Jennifer R. Brown, MD PhD, William G. Wierda, MD PhD, Anthony Letai, MD PhD, Donna S Neuberg, ScD, Wade Harper, PhD, Steven A. Carr, PhD, Federica Piccioni, PhD, Christopher J. Ott, PhD, Ignaty Leshchiner, PhD, Cory Johannessen, PhD, John G Doench, PhD, Vamsi Mootha, MD PhD, Gad Getz, PhD, Catherine J. Wu, MD
Blood (2018) 132 (Supplement 1): 893.
DOI: https://doi.org/10.1182/blood-2018-99-118604
Published: 2018
Journal Articles

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Rita Assi, MD, Hagop M. Kantarjian, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Christopher B. Benton, MD, Philip A. Thompson, MBBS, Gautam Borthakur, MD, Tapan M. Kadia, MD, Yesid Alvarado, MD, Elias J. Jabbour, MD, Marina Y. Konopleva, MD PhD, Koichi Takahashi, MD, Steven M. Kornblau, MD, Courtney D. DiNardo, MDMSc, Zeev E. Estrov, MD, Wilmer Flores, Sreyashi Basu, PhD, James P Allison, PhD, Padmanee Sharma, MD PhD, Sherry A. Pierce, BSN, BA, Allison Pike, RN, Jorge E. Cortes, MD, Farhad Ravandi, MD
Blood (2018) 132 (Supplement 1): 905.
DOI: https://doi.org/10.1182/blood-2018-99-116078
Published: 2018
Journal Articles

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study

Prithviraj Bose, MD, David McCue, Nathan P. Wiederhold, PharmD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Musa Yilmaz, MD, Koichi Takahashi, MD, Philip A. Thompson, MBBS, Naveen Pemmaraju, MD, Naval G. Daver, MD, Jan A. Burger, MD PhD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD PhD, Marina Y. Konopleva, MD PhD, Nitin Jain, MD, Courtney D. DiNardo, MD MSc, Yesid Alvarado, MD, Kiran Naqvi, MD MPH, Steven M. Kornblau, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Zeev E. Estrov, MD, Christopher B. Benton, MD, Lucia Masarova, MD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Caitlin R. Rausch, PharmD, Kayleigh Marx, PharmD, Wei Qiao, PhD, Xuelin Huang, PhD, Carol A. Bivins, RN, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Dimitrios P. Kontoyiannis, MD
Blood (2018) 132 (Supplement 1): 2674.
DOI: https://doi.org/10.1182/blood-2018-99-111727
Published: 2018
Journal Articles

Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Koji Sasaki, MD, Elias J. Jabbour, MD, Farhad Ravandi, MD, Nicholas J Short, MD, Guillermo Garcia-Manero, MD, Naval G. Daver, MD, Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Nitin Jain, MD, Ghayas C. Issa, MD, Victoria Jeanis, RN, Joie Alvarez, RN, Maria Khouri, Patrice Nasnas, MD, Rebecca E. Garris, MSc, William G. Wierda, MD PhD, Philip A. Thompson, MBBS, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD
Blood (2018) 132 (Supplement 1): 2695.
DOI: https://doi.org/10.1182/blood-2018-99-115212
Published: 2018
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Zeev E. Estrov, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD
Blood (2018) 132 (Supplement 1): 695.
DOI: https://doi.org/10.1182/blood-2018-185
Published: 2018